Virtual Library

  • +

    Best abstracts selected from submissions 2 (ID 2)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 11/08/2018, 16:20 - 17:00, Jade Ballroom
    • +

      OA03 - Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study (ID 106)

      16:20 - 17:00  |  Author(s): M.J. Hochmair, A. Morabito, D. Hao, C. Yang, R. Soo, J.C. Yang, R. Gucalp, B. Halmos, A. Golembesky, A. M, T. Cufer

      • Abstract

      Background:
      Afatinib has demonstrated efficacy in EGFR mutation-positive (EGFRm+) NSCLC; however, resistance develops over time, most commonly due to the emergence of the T790M mutation. Osimertinib has shown clinical activity in the treatment of T790M-positive disease following progression on a first-line tyrosine kinase inhibitor. Further information on outcomes of sequencing options is necessary to optimize treatment outcomes for patients.


      Method:
      This observational study is the first to evaluate outcomes of real-world patients who sequentially received first-line afatinib followed by osimertinib. Data were retrospectively collected between December 2017 and May 2018. Patients had common EGFRm+ (Del19, L858R) advanced NSCLC and acquired T790M after first-line afatinib. Patients must have completed afatinib treatment and started osimertinib treatment ?10 months prior to data entry. Patients with active brain metastases were excluded. The primary outcome was time on treatment (ToT) from initiation of afatinib until discontinuation of osimertinib.


      Results:
      A total of 204 patients were included in the study; of these, 24.5/67.6% were Asian and non-Asian (Caucasian and African American), 15.3% had ECOG performance status ?2, and 73.5/26.0% were Del19/L858R-positive. Overall median ToT was 27.6 months (90% CI: 25.9

    • +

      OA04 - Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After (ID 154)

      16:20 - 17:00  |  Author(s): T. Mizuno, H. Horinouchi, S. Watanabe, J. Sato, R. Morita, Y. Matsumoto, S. Murakami, Y. Goto, S. Kanda, Y. Fujiwara, N. Yamamoto, Y. Ohe

      • Abstract

      Background:
      Patients with EGFR-mutation-positive non-small-cell lung cancer (EGFR-NSCLC) who are treated with both cytotoxic chemotherapy and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have better survival outcomes than those who are only treated with EGFR-TKIs. Limited information is available about the factors that influence the non-administration of cytotoxic chemotherapies after the failure of EGFR-TKIs.


      Method:
      We reviewed the medical records of EGFR-NSCLC patients who received EGFR-TKIs as a first-line treatment at the National Cancer Center Hospital between January 2010 and December 2016. Computed tomography data regarding the number of metastatic organs, at the time of progressive disease (PD), which reflects the tumor burden, was retrieved. EGFR-TKIs use beyond PD was also investigated. We performed a multivariate logistic regression analysis to determine the factors influencing the non-administration of cytotoxic chemotherapies.


      Results:
      A total of 393 patients received EGFR-TKIs as a first-line treatment during the study period. After the exclusion of 96 patients who were receiving ongoing EGFR-TKIs treatment, 297 patients (103 men, 194 women) were included in this analysis. The median age was 68 years (range, 33?87 years), and 291 patients had an adenocarcinoma histology; 155 had deletions in exon 19, 132 had the L858R point mutation in exon 21, and 10 had other minor mutations. An Eastern Cooperative Oncology Group performance status (PS) of 0

  • +

    Best abstracts selected from submissions 7 (ID 5)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
    • +

      OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study (ID 211)

      16:20 - 17:00  |  Author(s): X. Li, L. Zhang, D. Jiang, Y. Wang, A. Zang, C. Ding, M. Zhao, W. Su, Y. Zhang, D. Zhong, J. Wu, G. An, C. Zhang, X. Hu, G. Cheng, H. Wang, Z. Han, X. He, J. Liu, L. Liang, S. Zhang

      • Abstract
      • Slides

      Background:
      NSCLC patients with 21 L858R mutation are less responsive to EGFR TKI treatment. This study aims to determine if high-dose icotinib can improve tumor response and progression-free survival (PFS) in this patient population.


      Method:
      In this randomized, open-label, multicenter phase II trial (INCREASE), patients with treatment-na

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (ID 67)

      16:20 - 17:00  |  Author(s): Y. Cheng, J. Zhou, S. Lu, Y. Zhang, J. Zhao, H. Pan, Y. Chen, C. Chian, R. Bruns, A. Johne, J. Scheele, Y. Wu

      • Abstract
      • Slides

      Background:
      Non-small cell lung cancer (NSCLC) can acquire resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs) via MET activation; dual MET/EGFR inhibition may have potential in EGFR TKI-resistant NSCLC. Tepotinib is a potent, selective MET TKI. We report randomized phase 2 data from a phase 1b/2 signal detection trial of tepotinib+gefitinib vs chemotherapy (pemetrexed + cisplatin/carboplatin) in patients with MET+/EGFR+T790M- NSCLC (NCT01982955).


      Method:
      Asian patients with advanced MET+ (IHC2+, IHC3+, gene amplification) NSCLC, acquired resistance to 1st-line EGFR TKI and ECOG performance status 0

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Parallel Session 1 - Biomarker detecting for lung cancer: new technique and new opinion (ID 1002)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 3
    • Moderators:
    • Coordinates: 11/08/2018, 16:20 - 17:00, Jade Ballroom
    • +

      Discussant - Sequencing or Combination? (ID 2006)

      16:20 - 17:00  |  Author(s): J Hu

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Standardization of molecular testing in China (ID 2005)

      16:20 - 17:00  |  Author(s): X Zhang

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      What is a trustworthy biomarker? (ID 2004)

      16:20 - 17:00  |  Author(s): C Manegold

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Parallel Session 1 - New strategy for neoadjuvant and adjuvant therapy (ID 1006)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 3
    • Moderators:
    • Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
    • +

      Discussion (ID 2016)

      16:20 - 17:00  |  Author(s): X Cai

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      New perspectives on neoadjuvant and adjuvant chemotherapy (ID 2014)

      16:20 - 17:00  |  Author(s): P Bunn

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      The translational research of neoadjuvant therapy (ID 2015)

      16:20 - 17:00  |  Author(s): W Zhong

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Parallel Session 3 - Diagnosis and treatment for small nodule in China (ID 1011)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 3
    • Moderators:
    • Coordinates: 11/10/2018, 16:20 - 17:00, Jade Ballroom
    • +

      A genomic study: How to Improve limit of detection of lung cancer liquid biopsy (ID 2030)

      16:20 - 17:00  |  Author(s): X Wang

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Early stage lung cancer: SBRT vs. surgery (ID 2029)

      16:20 - 17:00  |  Author(s): Z Zhu

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      How to deal with multiple pulmonary nodules (ID 2031)

      16:20 - 17:00  |  Author(s): W Li

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Special Symposia - What's new in the management of Squamous lung cancer? (ID 1014)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 11/10/2018, 16:20 - 17:00, Jade Ballroom
    • +

      Breakthrough in treating Squamous lung cancer: Current clinical progression and future perspectives (ID 2033)

      16:20 - 17:00  |  Author(s): H Yang

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      What we have known of the tumor and immuno biology of Squamous lung cancer? (ID 2032)

      16:20 - 17:00  |  Author(s): M Zhao

      • Abstract
      • Slides

      Abstract not provided

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.